Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (331-340 of 438) with videos related to

Pageof 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2017
Current and Emergent Therapy Options for Advanced Squamous Cell Lung CancerMark A Socinski, Coleman Obasaju, David Gandara, et al.
Clinical Lung Cancer|June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet StudyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2022
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMAJordi Remon, Benjamin Lacas, Roy Herbst, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.
Nature Medicine|March 17, 2023
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancerZoe June F Assaf, Wei Zou, Alexander D Fine, et al.
Cancers|June 20, 2019
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 InhibitorsMelanie Janning, Franca Kobus, Anna Babayan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 StudyMichael Boyer, Mehmet A N Şendur, Delvys Rodríguez-Abreu, et al.
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
Pageof 44

Showing results (331-340 of 438) with videos related to

Sort By:
Pageof 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2017
Current and Emergent Therapy Options for Advanced Squamous Cell Lung CancerMark A Socinski, Coleman Obasaju, David Gandara, et al.
Clinical Lung Cancer|June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet StudyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2022
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMAJordi Remon, Benjamin Lacas, Roy Herbst, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.
Nature Medicine|March 17, 2023
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancerZoe June F Assaf, Wei Zou, Alexander D Fine, et al.
Cancers|June 20, 2019
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 InhibitorsMelanie Janning, Franca Kobus, Anna Babayan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 StudyMichael Boyer, Mehmet A N Şendur, Delvys Rodríguez-Abreu, et al.
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
Pageof 44